Norepinephrine Infusion Preparation

### Drug Nomenclature - **Generic Name (INN)**: Norepinephrine (also known as Noradrenaline) - **Drug Class**: Sympathomimetic amine; direct-acting alpha-1 and beta-1 adrenergic receptor agonist - **ATC Code**: C01CA03 ### Preparation of Norepinephrine Infusion Standard preparation protocols for norepinephrine continuous infusion are as follows: | Component | Standard Protocol | |-----------|------------------| | **Standard Concentration** | 4 mg norepinephrine base (or 8 mg norepinephrine bitartrate) in 250 mL of D5W or NS | | **Resulting Concentration** | 16 mcg/mL (norepinephrine base) | | **Alternative Concentration** | 8 mg in 250 mL → 32 mcg/mL (for fluid-restricted patients) | ### Dosing Strategy for the Obese Patient (90 kg) Based on retrieved evidence, the following approach is recommended for this 90 kg patient with obesity (BMI ≥ 30 kg/m²): **Weight Descriptor Selection:** - For vasopressors administered as continuous infusions, either a **non-weight-based dosing regimen** or a **weight-based regimen using ideal body weight (IBW) or adjusted body weight (ABW)** is suggested for initial doses in obese patients [2]. - Norepinephrine is hydrophilic (negative log P), with distribution limited to the extracellular fluid compartment. Small volume of distribution and rapid clearance argue against using actual body weight (ABW) for dosing [2]. **Calculation of IBW for this patient:** - **IBW (Male)**: 50 kg + 0.9 kg per cm over 152 cm - **IBW (Female)**: 45.5 kg + 0.9 kg per cm over 152 cm - *Note: Height is required for precise IBW calculation. If height is unavailable, a conservative estimate would be approximately 65–70 kg for a 90 kg patient.* **Adjusted Body Weight (ABW):** - ABW = IBW + 0.4 × (Actual Body Weight − IBW) - *Example (assuming IBW = 65 kg)*: ABW = 65 + 0.4 × (90 − 65) = 65 + 10 = **75 kg** **Recommended Initial Dosing:** | Parameter | Recommendation | |-----------|---------------| | **Weight Descriptor** | IBW or ABW (not actual body weight) | | **Initial Infusion Rate** | 0.05–0.1 mcg/kg/min (using IBW or ABW) | | **Example for 75 kg (ABW)** | 3.75–7.5 mcg/min → 0.23–0.47 mL/hour of 16 mcg/mL solution | | **Titration** | Titrate to target MAP ≥ 65 mmHg, increasing by 0.05 mcg/kg/min every 5–10 minutes | | **Maximum Dose** | Typically up to 0.5–1.0 mcg/kg/min (using IBW/ABW) | ### Administration Instructions | Parameter | Detail | |-----------|--------| | **Route** | Continuous IV infusion via central line preferred (peripheral line acceptable for short-term use with close monitoring for extravasation) | | **Diluent** | D5W or NS | | **Stability** | Stable for 24 hours at room temperature; protect from light | | **Infusion Set** | Use dedicated IV line; avoid Y-site administration with alkaline solutions (e.g., sodium bicarbonate) | ### Key Safety Considerations 1. **Consistency across agents**: If using weight-based dosing, seek consistency between using IBW or ABW across different vasopressor agents (e.g., norepinephrine and dopamine) to minimize error risk [2]. 2. **Extravasation risk**: Norepinephrine is a vesicant. Monitor IV site closely; treat extravasation immediately with phentolamine 5–10 mg in 10–15 mL NS infiltrated subcutaneously. 3. **Hemodynamic monitoring**: Continuous arterial blood pressure monitoring is recommended for precise titration. 4. **Weaning considerations**: In critically ill patients with obesity, extubation while on low-dose norepinephrine (median 0.097 mcg/kg/min) was not associated with increased reintubation rates (16% vs. 17%, p = 0.85) [1]. --- ### Further Diagnostic Suggestions (Reference Only) To enable more precise dosing, if available, please consider providing: - **Patient height**: Required for accurate IBW calculation - **Patient sex**: Required for IBW formula selection - **Target MAP**: To guide titration endpoint --- *This information is based on retrieved evidence and general clinical pharmacology principles. Always verify against institutional protocols and official drug labeling. Clinical judgment should guide individual patient management.*